Literature DB >> 7884182

Reflux in untreated achalasia patients.

J P Shoenut1, A B Micflikier, C S Yaffe, B Den Boer, J M Teskey.   

Abstract

We made a prospective assessment of acid exposure in the distal esophagus in 48 consecutive untreated patients with achalasia using 24-h ambulatory esophageal pH studies. The majority of patients (38/48) experienced reflux that was within reported values for normal controls (total time pH < 4.0, 1.8 +/- 1.9%). Approximately 20% (10/48), however, demonstrated abnormal acid exposure (total time pH < 4.0, 18.8 +/- 14.8%). The difference in reflux expressed by these two groups was not due to a significant difference in lower esophageal sphincter pressure (p > 0.05) or retained food. An in vitro model of lactobacillus fermentation supported the contention that true acid reflux accounted for changes in esophageal pH. Repeat pH studies were obtained in 23 patients following treatment: 15 underwent pneumatic dilatation and 8 underwent limited myotomy. Although no significant differences were found between pre- and posttreatment reflux, some patients undergoing either treatment were found to demonstrate increased acid exposure. In conclusion, we believe that patients with achalasia should be tested by pH study both before and after treatment. Most of the patients who demonstrated significant pretreatment reflux were asymptomatic, and both methods that were used to decrease resting sphincter pressure were shown to be able to increase distal acid exposure.

Entities:  

Mesh:

Year:  1995        PMID: 7884182     DOI: 10.1097/00004836-199501000-00004

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  17 in total

1.  Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin.

Authors:  C Cuillière; P Ducrotté; F Zerbib; E H Metman; D de Looze; F Guillemot; H Hudziak; H Lamouliatte; J C Grimaud; A Ropert; M Dapoigny; R Bost; M Lémann; M A Bigard; P Denis; J L Auget; J P Galmiche; S Bruley des Varannes
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  Ambulatory esophageal pH testing. Referral patterns, indication, and treatment in a Canadian teaching hospital.

Authors:  J P Shoenut; C S Yaffe
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Impact of ingested liquids on 24-hour ambulatory pH tests.

Authors:  J P Shoenut; D Duerksen; C S Yaffe
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

4.  Reproducibility of ambulatory esophageal pH monitoring in the aperistaltic esophagus.

Authors:  J P Shoenut; A B Mieflikier; T A Aldor; C S Yaffe; D J Goldenberg
Journal:  Dysphagia       Date:  1996       Impact factor: 3.438

5.  Gastroesophageal reflux in achalasia. When is reflux really reflux?

Authors:  P F Crookes; S Corkill; T R DeMeester
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 6.  Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.

Authors:  Mitchell S Cappell; Stavros Nicholas Stavropoulos; David Friedel
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

7.  Achalasia developing years after surgery for reflux disease: case reports, laparoscopic treatment, and review of achalasia syndromes following antireflux surgery.

Authors:  E C Poulin; N E Diamant; P Kortan; P A Seshadri; C M Schlachta; J Mamazza
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

8.  Effect of pneumatic dilation on gastroesophageal reflux in achalasia.

Authors:  C A Burke; E Achkar; G W Falk
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

Review 9.  Evaluation and treatment of primary esophageal motility disorders.

Authors:  M G Patti; L W Way
Journal:  West J Med       Date:  1997-04

10.  Importance of preoperative and postoperative pH monitoring in patients with esophageal achalasia.

Authors:  M G Patti; M Arcerito; J Tong; A Wang; C V Feo; S J Mulvihill; L W Way
Journal:  J Gastrointest Surg       Date:  1997 Nov-Dec       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.